Botanix Pharmaceuticals Ltd has released a press release.
Botanix Initiates BTX 1702 Rosacea Study
Filed with ASX ·
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Botanix Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Botanix Pharmaceuticals
- Botanix Announces De-scheduling of Synthetic CBD
- Botanix Announces BTX 1503 Data and Progression to Phase 3
- BOT Receives Grant for Synthetic Cannabidiol Analog Program
- Botanix announces new clinical program to target rosacea
- Appendix 4E and Annual Report
Later from Botanix Pharmaceuticals
- Antimicrobial Platform Update and Launch of BTX 1801 Study
- Botanix Announces Top Line BTX 1204 Atopic Dermatitis Data
- Botanix Provides Update on Development Activities
- Botanix Provides Update on Development Activities Amended
- FDA Grants BTX 1801 QIDP Designation Status
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals